DuPont de Nemours, Inc. (DD) Stock Price & Analysis
DuPont de Nemours, Inc. (DD) closed at USD 135.1 on Thursday, October 22, 2026, up 0.71% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 134.15; the Oct 22, 2026 session ranged USD 131.4–135.15 on volume of 873,983 shares. Market capitalization is $18.24B, with a 52-week range of USD 100.02–157.98 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DD.md
Key facts (DD)
- Last four reported quarters (through Jun 30, 2026): revenue $6.99B, net income $55.0M (0.8% margin), free cash flow $702M (SEC filings).
- Valuation: P/E 331.7x (avg 26.6x at the last 2 fiscal year-ends), net debt $1.39B.
- 2 of 80 tracked superinvestors hold DD (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $13K; 1 not under a Rule 10b5-1 plan ($13K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.06 on a 1–5 scale) (18 analysts), mean target USD 165.47 (range 145–186).
- Total return with dividends: 1Y +34.7% vs S&P 500 +14.9%; 5Y +64.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.88, revenue estimate $1.84B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.6B | $13.0B | $6.61B | $6.72B | $6.85B | $6.99B |
| Gross profit | $4.59B | $4.62B | $2.17B | $2.22B | $2.36B | — |
| Net income | $6.47B | $5.87B | $423M | $703M | -$779M | $55.0M |
| EPS (diluted) | $14.92 | $14.75 | $2.82 | $5.04 | -$5.58 | — |
| Free cash flow | $1.49B | -$74.0M | $543M | $480M | $227M | $702M |
| Gross margin | 36.6% | 35.5% | 32.8% | 33.0% | 34.5% | — |
| Net margin | 51.5% | 45.1% | 6.4% | 10.5% | -11.4% | 0.8% |
| Revenue growth | -38.4% | +3.6% | -49.2% | +1.6% | +1.9% | — |
| Cash + short-term investments | $1.97B | $4.96B | $2.39B | — | — | — |
| Total debt | $10.8B | $8.45B | $7.86B | $7.17B | $3.13B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DD)
P/E 331.7x · P/S 2.6x · EV/Sales 2.8x · P/FCF 26.0x · P/B 1.3x · FCF yield 3.85% · Earnings yield 0.30% · Dividend yield (paid, TTM) 2.29% · Net debt $1.39B · EV $19.6B
P/E at fiscal year-ends: Dec 2024 19.0x, Dec 2023 34.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (DD)
2 of 80 tracked investors hold DD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 3.71% | $5.1M | Reduced -68.0% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $638K | Reduced -67.9% |
Insider sales (SEC Form 4, open-market, last ~7 months) (DD)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Koch Lori | CEO | 261 | $13K | 0.1% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DD)
Consensus Buy (mean 2.06 on a 1–5 scale), 18 analysts; mean target USD 165.47 (low 145, high 186).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | RBC Capital | Target lowered | Outperform | $176 → $160 |
| 2026-10-13 | Barclays | Initiated | Overweight | $156 |
| 2026-10-09 | JP Morgan | Downgrade | Overweight → Neutral | $172 → $145 |
| 2026-10-07 | Citigroup | Target lowered | Buy | $170 → $162 |
| 2026-10-05 | UBS | Target lowered | Buy | $178 → $172 |
| 2026-08-10 | JP Morgan | Target raised | Overweight | $171 → $172 |
| 2026-08-07 | RBC Capital | Target lowered | Outperform | $180 → $176 |
| 2026-08-05 | UBS | Target raised | Buy | $175 → $178 |
| 2026-07-02 | Citigroup | Target raised | Buy | $168 → $170 |
Total return (dividends reinvested) (DD)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +34.7% | +64.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.9% | +10.4% |
| Volatility (annualized) | 29.8% | 30.0% |
| Max drawdown | -18.6% (Feb 2026→Sep 2026) | -39.8% (Jan 2022→Sep 2022) |
DD revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Diversified Industrials | $963.0M | 52.9% | +3.3% |
| Healthcare & Water Technologies | $856.0M | 47.1% | +4.8% |
| Total revenue | $1.82B | 100% | — |
DD revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Industrial Technologies | $538.0M | 29.6% | +4.9% |
| Healthcare Technologies | $473.0M | 26.0% | +6.5% |
| Building Technologies | $425.0M | 23.4% | +1.4% |
| Water Technologies | $383.0M | 21.1% | +2.7% |
| Total revenue | $1.82B | 100% | — |
DD revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $809.0M | 44.5% | -1.3% |
| Asia Pacific | $454.0M | 25.0% | +7.1% |
| EMEA | $404.0M | 22.2% | +8.3% |
| China/Hong Kong | $198.0M | 10.9% | +7.6% |
| Other | $152.0M | 8.4% | +15.2% |
| Total revenue | $1.82B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
DD suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Qnity Electronics, Inc. (Q) | “•Tax Matters Agreement - entered into a Tax Matters Agreement with Qnity (the "Electronics Tax Matters Agreement").” |
| Partner | Corteva, Inc. (CTVA) | “4.Primarily related to the DWDP Separation and Distribution Agreement and Letter Agreement between Corteva and EIDP and the Electronics Separation and Distribution Agreement with Qnity.” |
| Partner | EIDP, Inc. (CTA-PB) | “4.Primarily related to the DWDP Separation and Distribution Agreement and Letter Agreement between Corteva and EIDP and the Electronics Separation and Distribution Agreement with Qnity.” |
Quoted from the company's 10-K filed Feb 17, 2026.
Companies that name DD in their SEC reports
| Relationship to DD | Company | Filing | Sentence |
|---|---|---|---|
| supplier | GRAHAM CORP (GHM) | 10-K Jun 8, 2026 | “A representative list of our customers include: 3M, Air Liquide, Anduril, Applied Research Laboratory at Pennsylvania State University, Aramco, Axiom Space, Bechtel Plant Machinery Inc., Blue Origin, Boeing, CERN, China State-owned Refiners, Cummins, Dow Chemical, DuPont, Echogen Power Systems, General Atomics, General Dynamics, GE Vernova, ExxonMobil, Fluor Corporation, Intuitive Machines, Jacobs Engineering Grou…” |
| competitor | LAKELAND INDUSTRIES INC (LAKE) | 10-K Apr 16, 2026 | “Three of our competitors, DuPont, Ansell, and MSA Safety, have substantially greater financial, marketing and sales resources than we do.” |
| partner | AirJoule Technologies Corp. (AIRJ) | 10-K Mar 31, 2026 | “Additionally, the AirJoule JV leases laboratory space at The Innovation Space in Wilmington's DuPont Experimental Station for coating formulation research, as well as a 12,000 square-foot facility in Schenectady, New York for research and development activities and to support ongoing collaboration efforts with GE Vernova's Advanced Research Center.” |
| competitor | ALPHA PRO TECH LTD (APT) | 10-K Mar 11, 2026 | “Our major competitors in the construction supply weatherization market are DuPont and Berry Global for housewrap and Owens Corning and GAF for synthetic roof underlayment.” |
| competitor | CODEXIS, INC. (CDXS) | 10-K Mar 11, 2026 | “There is competition from large industrial enzyme companies, such as Novozymes and DuPont, as well as subsidiaries of larger contract research/CMOs, such as DSM-Firmenich AG, Cambrex Corporation, Lonza Group, WuXi STA and Almac Group Ltd. Some fermentation pathway design companies, like Ginkgo Bioworks, whose traditional focus has been to design microorganisms that express small molecule chemicals, could extend in…” |
| partner | Caribou Biosciences, Inc. (CRBU) | 10-K Mar 5, 2026 | “On July 13, 2015, we entered into an Amended and Restated Collaboration and License Agreement (as amended, "Pioneer Agreement") with Pioneer (then a DuPont company) that superseded and replaced a prior Collaboration and License Agreement entered into on September 10, 2014.” |
| partner | Qnity Electronics, Inc. (Q) | 10-K Feb 26, 2026 | “In connection with the Spin-Off, we and/or certain of our subsidiaries have entered into various other agreements with DuPont and/or certain of its subsidiaries, including, but not limited to, the Tax Matters Agreement, the Employee Matters Agreement, the Transition Services Agreements, the Intellectual Property Cross-License Agreement, the Transitional House Marks Trademark License Agreement, the ESL Cost Sharing…” |
| supplier | Huntsman CORP (HUN) | 10-K Feb 18, 2026 | “Our amines customers include Afton, Bayer, Chevron, DuPont, Evonik, Hipower, Infineum, Lubrizol, Quadra Chemicals and Univar.” |
| partner | Corteva, Inc. (CTVA) | 10-K Feb 12, 2026 | “On April 1, 2019, the company entered into the Tax Matters Agreement with DuPont and Dow that allocates the responsibility for prior period consolidated taxes among Corteva, DuPont and Dow.” |
| competitor | Origin Agritech LTD (SEED) | 20-F Jan 30, 2026 | “We also face competition from the large multinational companies, including Pioneer (DuPont), Monsanto and Syngenta.” |
DD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.88 | $1.94 | -3.1% | $1.84B | 14 |
| Next quarter (ends Dec 2026) | $1.88 | $1.82 | +3.3% | $1.82B | 13 |
| Current fiscal year (ends Dec 2026) | $7.26 | $7.16 | +1.4% | $7.17B | 17 |
| Next fiscal year (ends Dec 2027) | $7.99 | $7.88 | +1.3% | $7.45B | 17 |
DD options: expected move
Options price a move of about ±8.0% (±$10.85) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±4.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 35.8% | ±8.0% |
| Dec 18, 2026 | 56 | 31.4% | ±9.9% |
| Jan 15, 2027 | 84 | 29.2% | ±11.2% |
| Mar 19, 2027 | 147 | 30.2% | ±15.2% |
| Apr 16, 2027 | 175 | 30.0% | ±16.4% |
| Jun 17, 2027 | 237 | 31.1% | ±19.7% |
| Sep 17, 2027 | 329 | 31.1% | ±23.1% |
30-day implied volatility 34.2% vs 20.4% realized over the last 30 trading days. Put/call ratio (volume) 0.03. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 135.1 |
|---|---|
| Change | ▲ 0.71% (up) |
| Previous Close | USD 134.15 |
| Open | USD 131.97 |
| Day Range | USD 131.4 – 135.15 |
| 52-Week Range | USD 100.02 – 157.98 |
| Volume | 873,983 shares |
| Market Cap | $18.24B |
| Exchange | NYQ |
Technical Analysis (DD)
Nexqual's technical model rates DD "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.93 (neutral) |
| vs SMA50 | Above (USD 132.63) |
| MACD | 0.28 (positive) |
Analyst Ratings (DD)
Wall Street analysts rate DD "Buy" based on 18 analysts, with a mean price target of USD 165.47 (range USD 145–186), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 165.47 |
| High Target | USD 186 |
| Low Target | USD 145 |
| Buy / Hold / Sell | 14 / 4 / 0 |
Earnings (DD)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 1.88 |
| Revenue Estimate | $1.84B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.88 vs est 1.76 ▲ beat |
| 2026-03-31 | USD 1.65 vs est 1.45 ▲ beat |
| 2025-12-31 | USD 1.38 vs est 1.29 ▲ beat |
| 2025-09-30 | USD 3.27 vs est 2.94 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (DD)
| Total Revenue | $6.99B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +4.00% |
| Gross Margin | +35.13% |
| Operating Margin | +14.24% |
| Profit Margin | +0.79% |
| ROE | +1.79% |
| Debt / Equity | 0.23 |
| Current Ratio | 2.43 |
| Total Cash | $1.74B |
| Total Debt | $3.18B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $702.00M (10.0% of revenue) |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (DD)
Nexqual rates DuPont de Nemours, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Critical — Revenue -45% YoY (annual), sharp decline |
|---|---|
| Profitability | Solid — Gross margin 35%, operating 14% (last 12 months) |
| Balance Sheet | Strong — $1.74B cash and investments vs $3.13B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $702M (last 4 quarters to Jun 2026, SEC), 10% margin |
| Efficiency | Weak — ROE 2%, ROA 2.1% |
Ownership (DD)
| Insider Ownership | +0.16% |
|---|---|
| Institutional Ownership | +80.08% |
| Shares Outstanding | 135.04M |
| Float | 134.46M |
| Short % of Float | +4.32% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (DD)
DuPont de Nemours, Inc. is led by Lori D. Koch, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| CEO & Director | Lori D. Koch |
|---|---|
| Senior VP & CFO | Antonella B. Franzen |
| President of Healthcare & Water Technologies | Jeroen Bloemhard |
| Chief Technology Officer | Marty DeGroot |
Major Backers & Investors (DD)
Notable institutional backers of DuPont de Nemours, Inc. include Invesco, Morgan Stanley, Victory Capital Management Inc., according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 2.81% |
| Morgan Stanley | 2.01% |
| Victory Capital Management Inc. | 1.74% |
| Goldman Sachs | 1.52% |
| Fidelity | 1.31% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 1.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.36% |
| BlackRock | 7.88% |
| State Street | 5.15% |
| Geode Capital | 2.77% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From DuPont de Nemours, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Legal & Regulatory Risks (Item 1A, quoted)
- The costs of complying with evolving regulatory requirements could negatively impact the Company's business, results of operations, financial condition and cash flows.
- The Company's business, results of operations and reputation could be adversely affected by industry-specific risks including process safety and product stewardship/regulatory compliance issues.
- Changes in the global and local tax regulatory environments in, and the distribution of income among, the various jurisdictions in which the Company operates, could adversely impact DuPont's results of operations.
- The Company's business, results of operations and reputation could be harmed by improper conduct by its employees, agents or business partners.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SQM | Sociedad Quimica y Minera S.A. | USD 56.37 | ▼ 3.54% |
| LYB | LyondellBasell Industries NV | USD 65.37 | ▲ 3.32% |
| IFF | International Flavors & Fragran | USD 93.83 | ▲ 3.08% |
| PPG | PPG Industries, Inc. | USD 113.09 | ▲ 2.65% |
| RPM | RPM International Inc. | USD 101.72 | ▲ 1.84% |
| ALB | Albemarle Corporation | USD 92.54 | ▼ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt